A Phase 2 interventional study of Levetiracetam in Epilepsy and Partial Onset Seizures, sponsored by UCB Japan Co. Ltd.. Completed at 4 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-03-07.
Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.
Among the 60 studies testing levetiracetam in Epilepsy, this one is the 51st largest by enrollment, is one of 5 that started in 2011, is one of 11 in phase 2, and was the 43rd registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Waad Alkathiri · Sites in Saudi Arabia
Ages 18+
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
National Taiwan University Hospital
Ages 20+
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 28 · Phase 4 13
First in 1998; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 60 interventional studies. Of the 55 that completed or were terminated, 31 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Japan Co. Ltd., one of the names counted as UCB S.A.. Under that name alone:
UCB Japan Co. Ltd. is the lead sponsor of 14 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 99th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2011, is one of 26 in phase 2, and was the 77th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing levetiracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety of Levetiracetam IV 15-minute infusion administered every 12 hours as adjunctive treatment in subjects with Partial Onset Seizures after switching from the equivalent Levetiracetam oral dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Twice daily intravenous (IV) infusion of Levetiracetam solution equivalent (mg-for-mg) to oral dose of Levetiracetam.
Drug: Levetiracetam
* Formulation: concentrate for solution for infusion * Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL) * Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day * Frequency: twice daily
Also known as: Keppra®, E Keppra®
Incidence of Treatment Emergent Adverse Events During the Entire Study Period (up to 32 Days)
An Adverse Event (AE) is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: During the entire Study Period from Screening (Day -14 to Day -1) over Evaluation Period (Day 1 to Day 4) to Follow-Up Period (Day 5 to Day 18)
Incidence of Treatment Emergent Serious Adverse Events During the Entire Study Period (up to 32 Days)
A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, results in significant or persistent disability/incapacity, is a congenital anomaly/birth defect (including that occurring in a fetus), or is an important medical event that may jeopardize the subject or may require medical or surgical intervention.
Time frame: During the entire Study Period from Screening (Day -14 to Day -1) over Evaluation Period (Day 1 to Day 4) to Follow-Up Period (Day 5 to Day 18)
Observed Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 1
Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 1.
Time frame: Day 1
Observed Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 4
Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 4.
Time frame: Day 4
Dose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 1
Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 1. Plasma trough concentration (Ctrough) was normalized to a dose of 500 mg as follows: Dose normalized Ctrough = Ctrough/last dose \[mg\] x 500 mg.
Time frame: Day 1
Dose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 4
Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 4. Plasma trough concentration (Ctrough) was normalized to a dose of 500 mg as follows: Dose normalized Ctrough = Ctrough/last dose \[mg\] x 500 mg.
Time frame: Day 4
Partial (Type 1) Seizure Frequency Per Day Over the Evaluation Period
Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.
Time frame: During the Evaluation Period (Day 1 to Day 4)
This study started to enroll subjects in July 2011 in order to end up with 4 centers in Japan. 16 subjects were treated and completed the study. All 16 subjects are included in the Safety Set.
| Milestone | Levetiracetam |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
An Adverse Event (AE) is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
| participants | Levetiracetam |
|---|---|
| Incidence of Treatment Emergent Adverse Events During the Entire Study Period (up to 32 Days) | 5 |
A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, results in significant or persistent disability/incapacity, is a congenital anomaly/birth defect (including that occurring in a fetus), or is an important medical event that may jeopardize the subject or may require medical or surgical intervention.
| participants | Levetiracetam |
|---|---|
| Incidence of Treatment Emergent Serious Adverse Events During the Entire Study Period (up to 32 Days) | 0 |
Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 1.
| micrograms per milliliter (µg/mL) | Levetiracetam |
|---|---|
| Observed Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 1 | 11.732 ± 63.1 |
Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 4.
| micrograms per milliliter (µg/mL) | Levetiracetam |
|---|---|
| Observed Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 4 | 11.632 ± 59.6 |
Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 1. Plasma trough concentration (Ctrough) was normalized to a dose of 500 mg as follows: Dose normalized Ctrough = Ctrough/last dose \[mg\] x 500 mg.
| micrograms per milliliter (µg/mL) | Levetiracetam |
|---|---|
| Dose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 1 | 6.611 ± 29.6 |
Plasma sample for determination of Plasma trough concentration of Levetiracetam was taken prior to intravenous infusion of Levetiracetam in the morning of Day 4. Plasma trough concentration (Ctrough) was normalized to a dose of 500 mg as follows: Dose normalized Ctrough = Ctrough/last dose \[mg\] x 500 mg.
| micrograms per milliliter (µg/mL) | Levetiracetam |
|---|---|
| Dose Normalized Plasma Trough Concentration of Levetiracetam Prior to Intravenous (iv) Infusion on Day 4 | 5.492 ± 29.4 |
Partial (Type I) seizures can be classified into one of the following three groups: Simple partial seizures, Complex partial seizures, Partial seizures evolving to secondarily generalized seizures.
| Seizures per day | Levetiracetam |
|---|---|
| Partial (Type 1) Seizure Frequency Per Day Over the Evaluation Period | 0.38 (0.00 to 1.00) |
Collected over Adverse Events (AEs) were collected over the entire Study Period from Screening (1 to 14 days prior to the first intravenous infusion) over Evaluation Period (4 days) to the end of Follow-Up Period (1 to 14 days after the final intravenous infusion).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levetiracetam | — | 0/16 (0%) | 5/16 (31.3%) |
| Event | Levetiracetam |
|---|---|
| GingivitisGastrointestinal disorders | 1/16 |
| ToothacheGastrointestinal disorders | 1/16 |
| Injection site inflammationGeneral disorders | 1/16 |
| Injection site painGeneral disorders | 1/16 |
| Injection site swellingGeneral disorders | 1/16 |
| ContusionInjury, poisoning and procedural complications | 1/16 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/16 |
| Age, Categorical(Participants) | Levetiracetam |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 16 |
| >=65 years | 0 |
| Age Continuous(years) | Levetiracetam |
|---|---|
| Mean | 32.9 ± 10.6 |
| Sex: Female, Male(Participants) | Levetiracetam |
|---|---|
| Female | 8 |
| Male | 8 |
| Region of Enrollment(participants) | Levetiracetam |
|---|---|
| Japan | 16 |
| Weight(kilogram) | Levetiracetam |
|---|---|
| Mean | 68.82 ± 12.38 |
| Height(centimeter) | Levetiracetam |
|---|---|
| Mean | 163.40 ± 8.95 |
The record gives a start of Jul 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam